| Target Price | HK$131.58 |
| Price | HK$99.70 |
| Potential |
31.98%
register free of charge
|
| Number of Estimates | 29 |
|
29 Analysts have issued a price target Innovent Biologics 2027 .
The average Innovent Biologics target price is HK$131.58.
This is
31.98%
register free of charge
HK$157.08
57.55%
register free of charge
HK$95.04
4.67%
register free of charge
|
|
| A rating was issued by 38 analysts: 35 Analysts recommend Innovent Biologics to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Innovent Biologics stock has an average upside potential 2027 of
31.98%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 15.24 | 22.11 |
| 38.42% | 45.11% | |
| EBITDA Margin | 11.14% | 17.17% |
| 181.59% | 54.19% | |
| Net Margin | 6.24% | 12.81% |
| 721.13% | 105.35% |
35 Analysts have issued a sales forecast Innovent Biologics 2026 . The average Innovent Biologics sales estimate is
This results in the following potential growth metrics:
34 Innovent Biologics Analysts have issued a net profit forecast 2026. The average Innovent Biologics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 0.55 | 1.63 |
| 885.71% | 196.36% | |
| P/E | 61.20 | |
| EV/Sales | 6.94 |
34 Analysts have issued a Innovent Biologics forecast for earnings per share. The average Innovent Biologics EPS is
This results in the following potential growth metrics and future valuations:
Innovent Biologics...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


